Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
135 hedge funds and large institutions have $204M invested in Antares Pharma, Inc. in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 34 reducing their positions, and 15 closing their positions.
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
18% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 34
6% more funds holding
Funds holding: 127 → 135 (+8)
1% less capital invested
Capital invested by funds: $205M → $204M (-$1.58M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
61% less call options, than puts
Call options by funds: $908K | Put options by funds: $2.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Silvercrest Asset Management
New York
|
+$6.67M |
| 2 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$2.51M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.47M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.43M |
| 5 |
MFAM
Motley Fool Asset Management
Alexandria,
Virginia
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$2.6M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$2.57M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.42M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$1.52M |
| 5 |
BC
Broadfin Capital
New York
|
-$1.34M |
ATRS Hedge Fund Activity: Q3 2019 in Review
135 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2019, worth a combined $204M — down 0.77% from $205M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ATRS positions and 15 closed out — a net gain of 9 holders — while 40 added to existing stakes and 34 trimmed.
The largest buyer was Silvercrest Asset Management, opening a new position worth an estimated $6.67M. The largest seller was Essex Investment Management, exiting entirely with an estimated $2.6M sold.
- 135 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2019, up from 127 in Q2 2019.
- Funds reported $204M of Antares Pharma, Inc. stock for Q3 2019, down 0.77% quarter-over-quarter.
- 24 funds opened new Antares Pharma, Inc. positions in Q3 2019 and 15 closed out, a net change of +9 holders.
- The largest Antares Pharma, Inc. buyer in Q3 2019 was Silvercrest Asset Management, an estimated $6.67M added.
- The largest Antares Pharma, Inc. seller in Q3 2019 was Essex Investment Management, an estimated $2.6M sold.
Based on aggregated 13F filings for Q3 2019.